$AMLX 0.51 Developing

Sentiment history

bullish neutral mixed bearish line = signal dashed = price

neutral 2

@wallstengine neutral 31 eng

$AMLX PHASE 3 TRIAL HITS PRIMARY ENDPOINT Amylyx said avexitide reduced Level 2 and Level 3 hypoglycemic events by 55% versus placebo in its Phase 3 LUCIDITY trial for post-bariatric hypoglycemia, with p=0.000003. The trial also met all secondary endpoints and showed no treatment-related serious adverse events. There are currently no FDA-approved treatments for PBH, which affects an estimated 160,000 people in the U.S. Amylyx plans to file an NDA by year-end, with a potential 2027 launch if approved.
view on X →
@TENETTRADEGROUP neutral 16 eng

Tenet Pre-Market Movers Aug.18.26 $AMLX $ENRD $FLXS $CHRS $DUOT $HAE $KURA $KLAR $FN $BIDU $HSAI $WDC $COHR $SNDK $VNET $INFQ $OUST $AMAT $ENTG $QBTS $LUNR $AMD $FLY $RKLB $GEV $NNE @ripster47 | @tenet_research | @TenetCharts https://t.co/9WTJhPiU0W
view on X →

Only one day of history so far — the signal arc fills in as the daily job runs.